Yinghong Wang

Yinghong Wang is a Senior Professor at The University of Texas MD Anderson Cancer Center. Her research focuses on immunology, oncology, and gastroenterology, with particular emphasis on immune checkpoint inhibitor-induced toxicities, inflammatory bowel disease, and cancer immunotherapy. She has published extensively on gastrointestinal immune-related adverse events (irAEs), including recent work in *Nature Reviews Cancer* on microbiota and irAEs, and in *Annals of Internal Medicine Clinical Cases* on hyperbaric oxygen for immunotherapy-induced colitis. Her investigations also explore STAT3 transcriptome signatures in high-risk colorectal cancer and the impact of proton pump inhibitors on checkpoint inhibitor therapy outcomes. She is recognized for advancing the management of multiorgan irAEs and hepatobiliary diseases in cancer patients.